1. Bloodstream infections (BSI) are a major cause of global mortality, and timely and reliable diagnosis is a continuing problem.
2. Current gold standard practices for pathogen identification and antibiotic sensitivity testing are time-consuming.
3. New technologies have been developed to provide accurate and timely diagnosis and antibiotic sensitivity tests, such as qPCR-HRM, SERS, Microfluidic-assisted whole blood compartmentalization before DNA amplification and analysis, and NGS detection directly from whole blood by Karius.
The article provides an overview of the current state of BSI diagnosis, highlighting its progress and shortcomings. The authors review recent advances in technology that have been approved for clinical use, noting that while they improve sensitivity and selectivity, they still cannot provide results in a timely manner. They then discuss some emerging technologies that may be able to reduce the overall turnaround time for BSI diagnosis by directly detecting whole blood while maintaining (or even improving) the current level of sensitivity and pathogen coverage.
The article is generally trustworthy in terms of its content; it provides an objective overview of the current state of BSI diagnosis with clear explanations of the various technologies discussed. The authors also provide evidence to support their claims about these technologies’ potential benefits in terms of accuracy, speed, and cost savings. However, there are some potential biases in the article that should be noted. For example, there is no discussion of possible risks associated with using these new technologies or any exploration of counterarguments to their use. Additionally, there is no mention of any potential ethical considerations related to using these technologies in clinical settings or any discussion about how they might affect patient outcomes or healthcare costs. Finally, there is no mention of any potential conflicts of interest among the authors or sources cited in the article.